Kiadis’ proprietary off-the-shelf NK-cell platform is based on NK-cells from a unique universal donor.
We have a pipeline of NK-cell therapies in development as adjunctive therapy for hematopoietic stem cell transplantation and as potential therapeutics for both liquid and solid tumors.
From our cell-based immunotherapy technology platform, we are developing therapeutics as adjunctive treatments for patients undergoing stem cell transplantation and as potentially curative treatments for patients with cancer. Our vision is to leverage the strengths of the human immune system to help patients with life-threatening diseases, by developing novel cell therapies that combine the innate and adaptive arms of the immune system.
Clinical trial: CR-AIR-009
ATIR (Allodepleted T-cell ImmunotheRapeutics) is no longer being developed by Kiadis.
Kiadis announced on November 12th, 2019 that it has completed a strategic portfolio review and has decided to change its strategy and focus all resources and investments on the company’s NK-cell therapy platform and product candidates. The company will discontinue development of ATIR101 and stop its ongoing phase 3 trial.